The journey from melanocytes to melanoma
PP Centeno, V Pavet, R Marais - Nature Reviews Cancer, 2023 - nature.com
Over the past decade, melanoma has led the field in new cancer treatments, with impressive
gains in on-treatment survival but more modest improvements in overall survival. Melanoma …
gains in on-treatment survival but more modest improvements in overall survival. Melanoma …
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies
L Succony, DM Rassl, AP Barker, FM McCaughan… - Cancer treatment …, 2021 - Elsevier
Adenocarcinoma has become the most prevalent lung cancer sub-type and its frequency is
increasing. The earliest stages in the development of lung adenocarcinomas are visible …
increasing. The earliest stages in the development of lung adenocarcinomas are visible …
RAF-MEK-ERK pathway in cancer evolution and treatment
Abstract The RAF-MEK-ERK signaling cascade is a well-characterized MAPK pathway
involved in cell proliferation and survival. The three-layered MAPK signaling cascade is …
involved in cell proliferation and survival. The three-layered MAPK signaling cascade is …
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Abstract The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …
[HTML][HTML] The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded
RJ Kurman, IM Shih - The American journal of pathology, 2016 - Elsevier
Since our proposal of a dualistic model of epithelial ovarian carcinogenesis more than a
decade ago, a large number of molecular and histopathologic studies were published that …
decade ago, a large number of molecular and histopathologic studies were published that …
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Melanoma treatment is being revolutionized by the development of effective
immunotherapeutic approaches,. These strategies include blockade of immune-inhibitory …
immunotherapeutic approaches,. These strategies include blockade of immune-inhibitory …
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
AS Guerreiro Stucklin, S Ryall, K Fukuoka… - Nature …, 2019 - nature.com
Infant gliomas have paradoxical clinical behavior compared to those in children and adults:
low-grade tumors have a higher mortality rate, while high-grade tumors have a better …
low-grade tumors have a higher mortality rate, while high-grade tumors have a better …
Unravelling mechanisms of p53-mediated tumour suppression
KT Bieging, SS Mello, LD Attardi - Nature Reviews Cancer, 2014 - nature.com
Abstract p53 is a crucial tumour suppressor that responds to diverse stress signals by
orchestrating specific cellular responses, including transient cell cycle arrest, cellular …
orchestrating specific cellular responses, including transient cell cycle arrest, cellular …
The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic
WW Zhang, L Li, D Li, J Liu, X Li, W Li, X Xu… - Human gene …, 2018 - liebertpub.com
Gendicine (recombinant human p53 adenovirus), developed by Shenzhen SiBiono
GeneTech Co. Ltd., was approved in 2003 by the China Food and Drug Administration …
GeneTech Co. Ltd., was approved in 2003 by the China Food and Drug Administration …
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
D Planchard, TM Kim, J Mazieres, E Quoix… - The Lancet …, 2016 - thelancet.com
Summary Background Activating BRAF V600E (Val600Glu) mutations are found in about 1–
2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in …
2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in …